Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status:
Completed
Trial end date:
2017-12-13
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC)
dosed three times every four weeks (3q4wk) in a mixed population of patients with specified
solid tumors.